Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA – GlobeNewswire (press release)
GlobeNewswire (press release) |
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
GlobeNewswire (press release) First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation. NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company … Abeona (ABEO) Receives FDA RMAT Designation for ABO-102 Gene Therapy in MPS IIIA |
